The abstract is read at the publisher; the summary is JClub's.
AVO-100, an AAV6 capsid with CD3scFv inserted into one capsid protein, achieved more than 200-fold higher transduction of primary human T cells and enabled complete eradication of CD19+ Raji xenografts.
- Why it matters: Natural AAV serotypes have been limited by poor transduction of non-activated human T cells, constraining in vivo CAR-T generation.
- What they did: The authors engineered CD3scFv into AAV capsid proteins (VP1/VP2/VP3), then tested AVO-100 in vitro for CD19-CAR expression and killing of CD19+ Raji cells and in NSG mice with Raji xenografts after a single intravenous dose of 2×10 8 vg per subject.
- The result: In vivo, AVO-100 prompted complete tumor eradication and significantly prolonged survival, while untreated control animals succumbed to progressive disease, supporting an off-the-shelf platform for B cell malignancies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.